Kaye has published research on GLP-1s in people with MS
Market Access Timeline Following Health Canada approval, generic manufacturers would need additional time for: Final production scaling and quality assurance Distribution network establishment Pricing negotiations with provincial drug plans Pharmacy inventory preparation The complete process from approval to widespread availability typically requires 2-3 additional months, suggesting fall 2026 for broad market access if summer approvals proceed as anticipated
The views expressed are those of the authors and not necessarily those of Jessie Gew and Alexandra Sinclair, the NIHR or the Department of Health and Social Care
That means you get real results, faster and more comfortably than ever
See updated 2026 data, side effects, and how Canadians can access it
During the same period a year ago, the company brought in $316 million in revenue